Advertisement

Device classes

  • Peter B. Luppa

Abstract

The market for POCT devices can be called labyrinthine – its intricate spectrum of methods spanning from simple test strips to complex immunochemical assays. It therefore makes sense to align a categorization of this technology along the following system characteristics: Sensor characteristics, system complexity, measurement principles, sample matrix and practical benefits.

References

  1. 1.
    Corstjens AM, Ligtenberg JJ, van der Horst IC, Spanjersberg R, Lind JS, Tulleken JE, et al. (2006) Accuracy and feasibility of point-of-care and continuous blood glucose analysis in critically ill ICU patients. Crit Care 10:R135CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dark P, Dean P, Warhurst G (2009) Bench-to-bedside review: the promise of rapid infection diagnosis during sepsis using polymerase chain reaction-based pathogen detection. Crit Care 13: 1–6CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Erhabor O, Richardson G, Mohammed I et al. (2013) Evaluation of the QBC Star centrifugal three-part differential haematology system. Br J Biomed Sci 70: 67–74CrossRefPubMedGoogle Scholar
  4. 4.
    Erickson KA, Wilding P (1993) Evaluation of a novel point-of-care system, the i-STAT portable clinical analyzer. Clin Chem 39: 283–287Google Scholar
  5. 5.
    Ganter MT, Hofer CK (2008) Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 106:1366–1375CrossRefGoogle Scholar
  6. 6.
    Goldmeyer J, Kong H, Tang W (2007) Development of a novel one-tube isothermal reverse transcription thermophilic helicase-dependent amplification platform for rapid RNA detection. J Mol Diagn 9: 639–644CrossRefPubMedGoogle Scholar
  7. 7.
    Herrmann S, Vonau W (2004) Online-Analyse mit Lab-on-Chip-Systemen. Technisches Messen 71: 613–618Google Scholar
  8. 8.
    Liedberg B, Nylander C, Lundstrom I (1995) Biosensing with surface plasmon resonance – how it all started. Biosens Bioelectron 10: i–ixCrossRefPubMedGoogle Scholar
  9. 9.
    Lippi G, Favaloro EJ, Plebani M (2011) Direct-to consumer testing: more risks than opportunities. Int J Clin Pract 65:1221–1229CrossRefPubMedGoogle Scholar
  10. 10.
    Luppa PB, Müller C, Schlichtiger A, Schlebusch H (2011) Point-of-care testing (POCT): Current techniques and future perspectives. Trends Anal Chem 30: 887–898CrossRefGoogle Scholar
  11. 11.
    Orth M, Luppa PB (2015) Direct-to-Consumer-Testing – Fluch oder Segen für die Patienten? Dtsch Ärztebl 112: A174–A176Google Scholar
  12. 12.
    Piepenburg O, Williams C, Stemple D, Armes N (2006) DNA detection using recombination proteins. PLoS Biol 4: e204CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Seme K, Mocilnik T, Komlos KF, Doplihar A, Persing DH, Poljak M (2008) GeneXpert enterovirus assay: one-year experience in a routine laboratory setting and evaluation on three proficiency panels. J Clin Microbiol 46: 1510–1513CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Spindel S, Sapsford K (2014) Evaluation of optical detection platforms for multiplexed detection of proteins and the need for point-of-care biosensors for clinical use. Sensors (Basel) 14: 22313–22341CrossRefPubMedGoogle Scholar
  15. 15.
    St John A (2004) Benchtop Instruments for Point-of-care Testing. In: Price CP, St John A, Hicks JM (eds) Point-of-care Testing, 2nd ed. AACC Press, Washington, pp 31–46Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Peter B. Luppa
    • 1
  1. 1.Klinikum rechts der TU MünchenInstitut für Klinische Chemie und PathobiochemieMünchenGermany

Personalised recommendations